Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, silodosin (Silodyx®) cannot be endorsed for use within NHS Wales for for the treatment of benign prostatic hyperplasia. |
||
|
||
Medicine details |
||
| Medicine name | silodosin (Silodyx®) | |
| Formulation | capsule | |
| Reference number | 461 | |
| Indication | For the treatment of benign prostatic hyperplasia |
|
| Company | Recordati Pharmaceuticals Ltd | |
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | Not available | |
| Date of issue | 26/04/2010 | |